Trial Profile
A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms HCV-SPRINT-2; SPRINT-2
- Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough; Schering-Plough Research Institute
- 15 Jun 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 05 Jun 2019 This trial has been discontinued in United Kingdom, according to European Clinical Trials Database.
- 16 Oct 2012 This trial has been discontinued in Portugal.